DHR Danaher saw its price target lowered to $220 from $260 at Stifel. Headline numbers for the second quarter were strong, but analysts said
DHR Danaher saw its price target lowered to $220 from $260 at Stifel. Headline numbers for the second quarter were strong, but analysts said the underperformance in its key bioprocessing business was "the obvious focal point." Guggenheim went to $200 from $235 for similar reasons. Truly disappointing. This is not the D